Share-based Payment Arrangement, Expense of Cytek Biosciences, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cytek Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Cytek Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,638,000, a 20% decline year-over-year.
  • Cytek Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $26,062,000, a 2.1% increase year-over-year.
  • Cytek Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $26,848,000, a 22% increase from 2023.
  • Cytek Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $22,048,000, a 33% increase from 2022.
  • Cytek Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $16,595,000, a 152% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cytek Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $26,062,000 $5,638,000 -$1,415,000 -20% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $27,477,000 $6,791,000 -$361,000 -5% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $27,838,000 $6,630,000 +$990,000 +18% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $26,848,000 $7,003,000 +$1,334,000 +24% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $25,514,000 $7,053,000 +$1,295,000 +22% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $24,219,000 $7,152,000 +$1,230,000 +21% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $22,989,000 $5,640,000 +$941,000 +20% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $22,048,000 $5,669,000 +$1,204,000 +27% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $20,844,000 $5,758,000 +$1,399,000 +32% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $19,445,000 $5,922,000 +$1,988,000 +51% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $17,457,000 $4,699,000 +$862,000 +22% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $16,595,000 $4,465,000 +$1,457,000 +48% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q3 2022 $15,138,000 $4,359,000 +$1,904,000 +78% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $13,234,000 $3,934,000 +$3,267,000 +490% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $9,967,000 $3,837,000 +$3,381,000 +741% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $6,586,000 $3,008,000 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
Q3 2021 $2,455,000 +$2,329,000 +1848% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $667,000 +$558,000 +512% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $456,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $126,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $109,000 01 Apr 2020 30 Jun 2020 10-Q 03 Sep 2021 2021 Q2

Cytek Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $26,848,000 +$4,800,000 +22% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $22,048,000 +$5,453,000 +33% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $16,595,000 +$10,009,000 +152% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
2021 $6,586,000 +$5,975,000 +978% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
2020 $611,000 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.